Early treatment of migraine attacks with triptans: A strategy to enhance outcomes and patient satisfaction?

Expert Review of Neurotherapeutics

Volumn 6, Issue 7, 2006, Pages 1087-1097

  D'Amico, Domenico ^a   Moschiano, Franca ^b   Bussone, Gennaro ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b A MANZONI HOSPITAL   (Italy)

Author keywords

Allodynia; Early intervention; Migraine; Mild pain; Outcomes; Patient satisfaction; Triptans

Indexed keywords

ANALGESIC AGENT; ELETRIPTAN; ERGOT DERIVATIVE; FROVATRIPTAN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; RIZATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

ALLODYNIA; COST BENEFIT ANALYSIS; HUMAN; MIGRAINE; PAIN ASSESSMENT; PATIENT EDUCATION; PATIENT SATISFACTION; REVIEW; TREATMENT OUTCOME;

CLINICAL TRIALS; CONSUMER SATISFACTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; MIGRAINE DISORDERS; OUTCOME ASSESSMENT (HEALTH CARE); PAIN MEASUREMENT; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; TREATMENT OUTCOME; TRYPTAMINES;

EID: 33745966705     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.7.1087     Document Type: Review

References (64)

1. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd Edition. Cephalalgia 24(Suppl. 1), 9-160 (2004).
2. Silberstein SD, Saper JR, Freitag FG. Migraine: Diagnosis and Treatment. In: Wolff' s Headache and Other Head Pain. Silberstein SD, Lipton RB, Dalessio DJ (Eds), Oxford University Press, NY, USA 121-237 (2001).
3. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41, 646-657 (2001).
4. Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia 2, 519-522 (2003).
5. Lanteri-Minet M, Valade D, Geraud G, Chautard MH, Lucas C. Migraine and possible migraine: results of FRAMIG 3, a French nation-wide survey carried out according to the 2004 IHS classification. Cephalalgia 25, 1146-1158 (2005).
6. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch. Intern. Med. 10, 255-259 (1999).
7. Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF. Migraine headache disability and health-related quality-of-life: a population-based case-control study from England. Cephalalgia 23, 441-450 (2003).
8. D'Amico D, Usai S, Grazzi L et al. The impact of primary headaches on patients' lives: Italian experience with the MIDAS and the SF-36 questionnaires. Headache Care 1, 123-128 (2004).
9. Dueland AN, Leira R, Burke TA, Bolge S. The impact of migraine on work, family, and leisure among young women - a multinational study. Curr. Med. Res. Opin. 20, 1595-1604 (2004).
10. Solomon GD, Santanello N. Impact of migraine and migraine therapy on productivity and quality of life. Neurology 55(Suppl. 2), S29-S36 (2000).
11. Dueland AN, Leira R, Cabelli ST. The impact of migraine on psychological wellbeing of young women and their communication with physicians about migraine: a multinational study. Curr. Med. Res. Opin. 21, 1297-1305 (2005).
12. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and labor costs of migraine in the US. Pharmacoeconomics 2, 67-76 (1992).
13. Terwindt GM, Ferrari MD, Tijhuis M, Groenen SM, Picavet HS, Launer LJ. The impact of migraine on quality of life in the general population: the GEM study. Neurology 55, 624-629 (2000).
14. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 55, 754-762 (2000). •• Comprehensive treatment guidelines for migraine, provided by the US Headache Consortium (which includes seven organizations and scientific societies) based on an analysis of published evidence; general principles of management together with goals of acute treatment and indications regarding the use of triptans in the acute therapy of migraine are also provided.
15. Dowson AJ, Lipscombe S, Sender J, Rees T, Watson D. Migraine in primary care advisors. New guidelines for the management of migraine in primary care. Curr. Med. Res. Opin. 18, 414-439 (2002).
16. Humphrey PPA. How it started. Cephalalgia 21, 2-5 (2001).
17. Humphrey PP. 5-Hydroxytryptamine and the pathophysiology of migraine. J. Neurol. 238(Suppl. 1), S38-S44 (1991).
18. 1B/1D receptor agonists in the acute treatment of migraines. In: The Headaches. Third Edition. Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA (Eds), Lippincott Williams & Wilkins, Philadelphia, USA, 469-503 (2006). •• Updated review of the pharmacology, possible mechanisms of action and randomized clinical trial results of all marketed triptans.
19. Tfelt-Hansen P. A comparative review for pharmacology, pharmacokinetics and efficacy of triptans in migraine. Drugs 6, 1259-1287 (2000).
20. 1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22, 633-658 (2002). •• A milestone paper for our understanding of triptan efficacy in migraine: an evidence-based meta-analysis of the results of 53 oral triptan trials, with ample discussion of methodological issues and global evaluations of efficacy and tolerability.
21. Brandes JL. Global trends in migraine care: results from the MAZE survey. CNS Drugs 16(Suppl. 1), 13-18 (2002).
22. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 39(Suppl. 2), S20-S26 (1999).
23. Cady RK, Lipton RB, Hall C, Stewart WF, O'Quinn S, Gutterman D. Treatment of mild headache in disabled migraine sufferers: results of the Spectrum Study. Headache 40(10), 792-797 (2000). • The first study to suggest that triptan efficacy might be enhanced by treating the migraine attack when the pain is mild, through a post hoc analysis of a subgroup of patients.
24. Cady RK, Sheftell F, Lipton RB et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin. Ther. 22(9), 1035-1048 (2000).
25. Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 42, 28-31 (2002).
26. Mathew N. Early intervention with almotriptan improves sustained pain-free response in acute migraine. Headache 43, 1075-1079 (2003).
27. Winner P, Mannix LK, Putnam DG et al. Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo controlled studies. Mayo Clin. Proc. 78, 1214-1222 (2003).
28. Dowson AJ, Massiou H, Lainez JM, Caborrocas X. Almotriptan improves response rates when treatment is within 1 hour of migraine onset. Headache 44, 318-322 (2004).
29. Klapper J, Lucas C, Rosio O, Charlesworth B on behalf of the ZODIAC study group. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia 24, 918-924 (2004).
30. Scholpp J, Schellenberg R, Moeckesch B, Banik N. Early treatment of a migraine attack while pain is still increases the efficacy of sumatriptan. Cephalalgia 24, 925-933 (2004). • The first study to prospectively compare early and delayed administration of sumatriptan, although with an open-label design.
31. Carpay J, Schoenen J, Ahmad F, Kinrade F, Boswell D. Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study. Clin. Ther. 26, 214-223 (2004).
32. Cady R, Elkind A, Goldstein J, Keywood C. Randomized, placebocontrolled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr. Med. Res. Opin. 20(9), 1465-1472 (2004). •• A prospective controlled study that provides a direct comparison of the effects of early versus delayed intervention with the same triptan.
33. Mathew NT, Kailasam J, Meadors L. Early treatment of migraine with rizatriptan: a placebo-controlled study. Headache 44(7), 669-673 (2004). •• The cross-over design of the study allows a within-patient comparison of the effects of early versus delayed intervention with a single triptan.
34. Brandes JL, Kudrow D, Cady R, Tiseo PJ, Sun W, Sikes CR. Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Cephalalgia 25(9), 735-742 (2005). •• The study provides a direct comparison of the effects of early versus delayed intervention with the same triptan, and allows speculation concerning the relative importance of pain intensity at administration and the timing of administration (< 1 h vs ≥ 1 h).
35. Winner P, Landy S, Richardson M, Ames M. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials. Clin. Ther. 27, 1785-1794 (2005).
36. Lofland JH, Johnson NE, Batenhorst AS, Nash DB. Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective. Arch. Intern. Med. 159(18), 2228 (1999).
37. Dasbach EJ, Carides GW, Gerth WC, Santanello NC, Pigeon JG, Kramer MS. Work and productivity loss in the rizatriptan multiple attack study. Cephalalgia 20(9), 830-834 (2000).
38. Santanello NC, Polis AB, Hartmaier SL, Kramer MS, Block GA, Silberstein SD. Improvement in migraine-specific quality of life in a clinical trial of rizatriptan. Cephalalgia 17(8), 867-872 (1997).
39. Lainez MJ, Lopez A, Pascual AM. Effects on productivity and quality of life of rizatriptan for acute migraine: a workplace study. Headache 45(7), 883-890 (2005).
40. Colman SS, Brod MI, Krishnamurthy A, Rowland CR, Jirgens KJ, Gomez-Mancilla B. Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Clin. Ther. 23(1), 127-145 (2001).
41. Biddle AK, Shih YC, Kwong WJ. Cost-benefit analysis of sumatriptan tablets versus usual therapy for treatment of migraine. Pharmacotherapy 20, 1356-1364 (2000).
42. Ceballos Hernansanz MA, Sanchez Roy R, Cano Orgaz A, Lopez-Gil A, START 10 Study Group. Migraine treatment patterns and patient satisfaction with prior therapy: a substudy of a multicenter trial of rizatriptan effectiveness. Clin. Ther. 25(7), 2053-2069 (2003).
43. Powers C, Szeto S, Pangtay D, Bort T, Cervi M, Cady R. Evaluation of migraineurs' preferences for naratriptan over conventional first-line agents. Arch. Fam. Med. 9(8), 753-758 (2000).
44. Goadsby PJ, Dodick DW, Ferrari MD, McCrory DC, Williams P. TRIPSTAR: prioritizing oral triptan treatment attributes in migraine management. Acta Neurol. Scand. 110(3), 137-143 (2004).
45. Davies GM, Santanello N, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia 20, 554-560 (2000).
46. Ferrari MD. Should we advise patients to treat migraine attacks early? Cephalalgia 24, 915-918 (2004). • An interesting and stimulating editorial on the evidence then available from published studies, followed by a discussion of methodological problems and suggestions for the optimal design for early treatment trials.
47. Cady RK, Sheftell F, Lipton RB, Kwong WJ, O'Quinn S. Economic implications of early treatment of migraine with sumatriptan tablets. Clin. Ther. 23, 284-291 (2001).
48. Halpern MT, Lipton RB, Cady RK, Kwong WJ, Marlo KO, Batenhorst AS. Costs and outcomes of early versus delayed migraine treatment with sumatriptan. Headache 42, 984-999 (2002).
49. Kwong WJ, Taylor FR, Adelman JU. The effect of early intervention with sumatriptan tablets on migraine-associated productivity loss. Occup. Environ. Med. 47(11), 1167-1173 (2005).
50. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann. Neurol. 47(5), 614-624 (2000).
51. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 89, 107-110 (2001).
52. Burstein R, Jakubowski M. Analgesic triptan action in a animal model of intracranial pain: a race against the development of central sensitization. Ann. Neurol. 55(1), 27-36 (2004). • An important study offering new insights into the pathophysiology of migraine attacks, based on the concept of central sensitization/cutaneous allodynia and on the inability of triptans to reverse these phenomena in an animal model.
53. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann. Neurol. 55, 19-26 (2004). • Clinical application of insights obtained from animal studies on sensitization/cutaneous allodynia. Investigates the relationship between development of allodynia in migraine patients and variation in outcome of triptan therapy.
54. Lipton RB, Bigal ME, Rush SR et al. Migraine practice patterns among neurologists. Neurology 62(11), 1926-1931 (2004).
55. Foley KA, Cady R, Martin V et al. Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraine. Headache 45(5), 538-545 (2005).
56. Moschiano F, D'Amico D, Allais G et al. Early triptan intervention in migraine: an overview. Neurol. Sci. 26(Suppl. 2), 108-110 (2005).
57. Stang PE, VonKorff M. The diagnosis of headache in primary care: factors in the agreement of clinical and standardized diagnoses. Headache 34, 138-142 (1995).
58. Kavuk I, Katsarava Z, Selekler M et al. Clinical features and therapy of medication overuse headache. Eur. J. Med. Res. 9(12), 565-569 (2004).
59. Saper JR, Dodick D, Gladstone JP. Management of chronic daily headache: challenges in clinical practice. Headache 45(Suppl. 1), S74-S85 (2005).
60. Meletiche DM, Lofland JH, Young WB. Quality-of-life differences between patients with episodic and transformed migraine. Headache 41, 573-578 (2001).
61. Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache 43, 336-342 (2003).
62. D'Amico D, Grazzi L, Usai S, Rigamonti A, Curone M, Bussone G. Disability pattern in chronic migraine with medication overuse: a comparison with migraine without aura. Headache 45(5), 553-560 (2005).
63. Fruhstorfer H, Lindblom U, Schmidt WC. Method for quantitative estimation of thermal thresholds in patients. J. Neurol. Neurosurg. Psychiatry 39, 1071-1075 (1976).
64. Jakubowski M, Silberstein S, Ashkenazi A, Burstein R. Can allodynic migraine patients be identified interictally using a questionnaire? Neurology 65, 1419-1422 (2005).